Affiris Announces Phase 2 Study of Potential Parkinson’s Vaccine

Affiris Announces Phase 2 Study of Potential Parkinson’s Vaccine
Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful, could lead to a vaccine against  Parkinson’s disease. Affitope triggers the production of antibodies — molecules that recognize specific targets — against alpha-synuclein, a protein found in the brain that may be involved in transmitting information between neurons. While its precise function remains ... read more
Source: Parkinson’s News TodayPublished on 2020-01-14By Forest Ray